Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 29, 2007 Brian Lawler	The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.
The Motley Fool June 11, 2008 Brian Lawler	Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals?
The Motley Fool November 2, 2007 Brian Lawler	A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool September 18, 2007 Brian Lawler	Direct Your Attention to DURECT Promising drug test results make DURECT a company to watch. The tiny drugmaker has a host of important milestones coming up over the next year.
The Motley Fool November 10, 2005 W.D. Crotty	Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%.
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool May 28, 2008 Brian Lawler	King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another.
The Motley Fool December 11, 2008 Brian Orelli	A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone.
The Motley Fool April 1, 2008 Brian Lawler	A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics.
The Motley Fool May 2, 2007 Brian Lawler	Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about.
The Motley Fool April 26, 2011 Brian Orelli	We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.
The Motley Fool November 5, 2007 Brian Lawler	King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note.
The Motley Fool June 27, 2011 Brian Orelli	Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections.
The Motley Fool June 24, 2011 Brian Orelli	Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why?
The Motley Fool January 6, 2012 David Williamson	Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares.
The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
The Motley Fool May 5, 2008 Brian Lawler	Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week.
The Motley Fool March 3, 2009 Robert Steyer	Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.
The Motley Fool March 30, 2005 David Nierengarten	Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives?
The Motley Fool May 15, 2007 Brian Lawler	King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years.
The Motley Fool March 1, 2007 Brian Lawler	King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter.
The Motley Fool June 20, 2011 Brian Orelli	Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next.
The Motley Fool July 18, 2007 Brian Orelli	Pain-Free Payday for DURECT Results from a trial take it one step closer to possible approval for a local anesthetic. Because the platform can be used with different types of drugs, DURECT could try to win additional partnerships.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool July 6, 2007 Brian Orelli	Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing.
The Motley Fool August 29, 2011 Brian Orelli	A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool August 14, 2009 Brian Orelli	The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet.
The Motley Fool July 24, 2007 Brian Lawler	Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it.
The Motley Fool October 31, 2007 Brian Lawler	Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.
The Motley Fool September 12, 2008 Brian Lawler	King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders.
BusinessWeek June 14, 2004 Gene G. Marcial	From Pain Therapeutics: A Better Pain Killer Remoxy, now in proof-of-concept trials, could become the replacement for the most popular opioid pain killer OxyContin, with a potential $1 billion market.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool August 22, 2007 Brian Orelli	Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
The Motley Fool June 22, 2011 Brian Orelli	Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica.
The Motley Fool July 10, 2007 Brian Lawler	Adolor Tries Again Adolor continues work on its second drug candidate. Investors will have to wait until early 2008 for some data to sink their teeth into.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool May 17, 2007 Mike Havrilla	Javelin Is Right on Target The company reformulates existing drugs to fill unmet needs, making its stock worthy of consideration.
The Motley Fool December 1, 2008 Brian Orelli	It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies.
The Motley Fool May 18, 2009 Brian Orelli	Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
The Motley Fool December 9, 2008 Brian Orelli	Presents or Coal From the FDA? Let's take a look at a few companies expecting FDA decisions this month and see whether they're more likely to get a present or a lump of coal in their marketing-application stockings.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool April 14, 2009 Brian Orelli	Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge.